Immunoprecise Antibodies Ownership
| IPA Stock | USD 0.41 0.03 7.89% |
Shares in Circulation | First Issued 1997-03-31 | Previous Quarter 26.9 M | Current Value 27.1 M | Avarage Shares Outstanding 5 M | Quarterly Volatility 8.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Immunoprecise |
Immunoprecise Stock Ownership Analysis
About 12.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immunoprecise Antibodies recorded a loss per share of 0.77. The entity last dividend was issued on the 23rd of November 2020. The firm had 1:5 split on the 23rd of November 2020. ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies is traded on NASDAQ Exchange in the United States. To learn more about Immunoprecise Antibodies call Jennifer Bath at 250 483 0308 or check out https://www.ipatherapeutics.com.Besides selling stocks to institutional investors, Immunoprecise Antibodies also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Immunoprecise Antibodies' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Immunoprecise Antibodies' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Immunoprecise Antibodies Quarterly Liabilities And Stockholders Equity |
|
About 12.0% of Immunoprecise Antibodies are currently held by insiders. Unlike Immunoprecise Antibodies' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Immunoprecise Antibodies' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Immunoprecise Antibodies' insider trades
Immunoprecise Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunoprecise Antibodies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunoprecise Antibodies backward and forwards among themselves. Immunoprecise Antibodies' institutional investor refers to the entity that pools money to purchase Immunoprecise Antibodies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rathbone Brothers Plc | 2024-06-30 | 14 K | Ubs Group Ag | 2024-06-30 | 12.2 K | Mariner Wealth Advisors Llc | 2024-06-30 | 10 K | Simplex Trading, Llc | 2024-06-30 | 7.6 K | Group One Trading, Lp | 2024-06-30 | 2.4 K | West Paces Advisors Inc | 2024-09-30 | 1.7 K | Citigroup Inc | 2024-09-30 | 7.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Royal Bank Of Canada | 2024-06-30 | 0.0 | Ingalls & Snyder Llc | 2024-09-30 | 1.6 M | Renaissance Technologies Corp | 2024-09-30 | 60.3 K |
Immunoprecise Antibodies Outstanding Bonds
Immunoprecise Antibodies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunoprecise Antibodies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunoprecise bonds can be classified according to their maturity, which is the date when Immunoprecise Antibodies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.